Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Intangibles: 2018-2025

  • Ultragenyx Pharmaceutical's Change in Intangibles rose 50.00% to $15.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $30.0 million, marking a year-over-year decrease of 25.42%. This contributed to the annual value of $12.5 million for FY2024, which is 400.00% up from last year.
  • Ultragenyx Pharmaceutical's Change in Intangibles amounted to $15.0 million in Q1 2025, which was up 500.00% from $2.5 million recorded in Q2 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Change in Intangibles peaked at $30.0 million during Q1 2022, and registered a low of $2.5 million during Q2 2023.
  • For the 3-year period, Ultragenyx Pharmaceutical's Change in Intangibles averaged around $7.5 million, with its median value being $6.2 million (2023).
  • Data for Ultragenyx Pharmaceutical's Change in Intangibles shows a peak YoY skyrocketed of 50.00% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Ultragenyx Pharmaceutical's Change in Intangibles stood at $30.0 million in 2022, then reached $2.5 million in 2023, then remained steady at $2.5 million in 2024, then spiked by 50.00% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q1 2025, $2.5 million for Q2 2024, and $10.0 million during Q1 2024.